VEGFxxxb Biomarker Detection for Pre-eclampsia Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting pre-eclampsia are inconsistent due to conflicting results from different measurement techniques, and there is a lack of effective early markers for predicting the condition, which complicates timely intervention.
Innovation Solution
Detecting the level of VEGFxxxb, specifically VEGF165b, in maternal plasma before the end of the second trimester and comparing it to a reference level to identify the risk of pre-eclampsia, with the option to administer VEGFxxxb active agents to increase levels and reduce the risk of the condition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional sandwich ELISA is used to measure VEGF levels, then the measurement is simple and widely available, but the results are inconsistent and may not reflect true VEGF levels due to interference from circulating binding proteins
Solution Approach 1:
The patent extracts and measures only the free, unbound form of VEGFxxxb using highly specific antibodies that recognize epitopes not blocked by circulating binding proteins. This extraction approach isolates the biologically active fraction of VEGF from the complex plasma environment, resolving the measurement inconsistency problem.
Solution Approach 2:
The patent introduces a competitive binding assay system where labeled VEGFxxxb competes with endogenous VEGFxxxb for antibody binding sites. This intermediary competitive binding mechanism allows indirect measurement of free VEGFxxxb levels while avoiding direct interference from circulating binding proteins that block sandwich ELISA.
2Measurement precision
If VEGF levels are measured using radioimmunoassay or competitive enzyme immunoassay, then the measurement reflects total VEGF including bound forms, but the methodology is more complex and less widely available
Solution Approach 1:
The patent changes the detection parameter from measuring total VEGF (bound + unbound) to specifically measuring free, unbound VEGFxxxb. This parameter change is achieved through careful selection of antibody epitopes and assay conditions that favor detection of the unbound form, simplifying the clinical interpretation of VEGF status in pre-eclampsia risk.
3Reliability
If VEGFxxxb levels are monitored throughout pregnancy, then early risk prediction is possible, but the cost and frequency of monitoring increases
Solution Approach 1:
The patent performs preliminary measurement of free VEGFxxxb levels in the first trimester (before 13 weeks gestation) to predict pre-eclampsia risk before the condition develops. This preliminary action allows early identification of high-risk patients who can then receive preventive treatment such as low-dose aspirin, avoiding the need for frequent ongoing monitoring.
Data Source
AI summary
A method of detecting a risk of a pregnant female mammal developing pre-eclampsia or a complication linked thereto, or of a fetus of the pregnant female mammal developing a fetal or neonatal deficiency linked to maternal pre-eclampsia, comprises detecting the level of a VEGFxxxb in a sample from the pregnant female mammal at less than about 24 weeks of gestation and comparing the detected level with a reference level. A reduced level in the sample from the pregnant female mammal is indicative of a risk of the pregnant female mammal developing pre-eclampsia or a complication linked thereto or of the fetus developing the fetal or neonatal deficiency linked to maternal pre-eclampsia.